Event Recordings
Day 1 | Day 2
Day 2 Introduction & Welcome
Joseph Wu, M.D., Ph.D.
Director, Stanford Cardiovascular Institute
Simon H. Stertzer, M.D., Professor of Medicine and Radiology
Session VI: Research Development III
Moderator: Kathleen Giacomini, PhD | Co-Moderator: Kuldev Singh, MD
Full Session
Moderator: Kathleen Giacomini, Ph.D.
Prof of Bioengineering & Co-Dir UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, UCSF
Co-Moderator: Kuldev Singh, M.D.
Professor of Ophthalmology, Stanford University School of Medicine
Speakers:
Aida Habtezion, M.D.
Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer
Translating Lessons from the Covid-19 Programs
Mathai Mammen, M.D., Ph.D.
Executive Vice President, Pharmaceuticals, R&D, Johnson& Johnson
Raising the Bar for Innovation
Peter Marks, M.D., Ph.D.
Director, Center for Biologics Evaluation and Research, U.S. FDA
Facilitating the Development and Manufacturing of COVID-19 Vaccines
Panel Discussion
Translating Lessons from the Covid-19 Programs
Aida Habtezion, MD
Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer
Raising the Bar for Innovation
Mathai Mammen, MD, PhD
Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson
Facilitating the Development and Manufacturing of COVID-19 Vaccines
Peter Marks, MD, PhD
Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Panel Discussion
Moderator: Kathleen Giacomini, Ph.D.
Prof of Bioengineering & Co-Dir UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, UCSF
Co-Moderator: Kuldev Singh, M.D.
Professor of Ophthalmology, Stanford University School of Medicine
Speakers:
Aida Habtezion, M.D.
Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer
Mathai Mammen, M.D., Ph.D.
Executive Vice President, Pharmaceuticals, R&D, Johnson& Johnson
Peter Marks, M.D., Ph.D.
Director, Center for Biologics Evaluation and Research, U.S. FDA
Session VII : Fireside Chat with Fireside Chat with Katalin Karikó, PhD and Dean Lloyd Minor, MD
Moderator: Dean Lloyd Minor, MD | Co-Moderator: Sanjay Malhotra, PhD
Fireside Chat with Katalin Karikó, Ph.D.
Senior Vice President, BioNTech
Moderator: Dean Lloyd Minor, M.D.
Dean, Stanford School of Medicine
Co-Moderator: Sanjay Malhotra, Ph.D.
Professor, Cell, Developmental & Cancer Biology; Director, Center for Experimental Therapeutics, OHSU
Session VIII: Investing in Discovery
Moderator: Amy L. Chang, MSEE | Co-Moderator: Sanjay Malhotra, PhD
Full Session
Moderator: Amy L. Chang, M.S.E.E.
Board of Directors at The Walt Disney Co, Procter & Gamble, Marqeta, and Pragma Platform
Co-Moderator: Sanjay Malhotra, Ph.D.
Professor, Cell, Developmental & Cancer Biology; Director, Center for Experimental Therapeutics, OHSU
Speakers:
Joe Jimenez, M.B.A
Co-Founder and Managing Director, Aditum Ventures
The Evolving Role of Venture Capital in the Pharma Ecosystem
David Goel
Founder & Managing General Partner, Matrix Capital Management
The Convergence of Technology and the Life Sciences
Jonathan MacQuitty, Ph.D.
Sector Head for Life Sciences, Lightspeed Ventures
A New Approach to Healthcare Investing
Margarita Chavez, J.D.
Managing Director, AbbVie Ventures
Panel Discussion
The Evolving Role of Venture Capital in the Pharma Ecosystem
Joe Jimenez, MBA
Aditum Ventures
The Convergence of Technology and the Life Sciences
David Goel
Founder & Managing General Partner, Matrix Capital Management
A New Approach to Healthcare Investing
Jonathan MacQuitty, PhD
Sector Head for Life Sciences, Lightspeed Ventures
Panel Discussion
Moderator: Amy L. Chang, M.S.E.E.
Board of Directors at The Walt Disney Co, Procter & Gamble, Marqeta, and Pragma Platform
Co-Moderator: Sanjay Malhotra, Ph.D.
Professor, Cell, Developmental & Cancer Biology; Director, Center for Experimental Therapeutics, OHSU
Speakers:
Joe Jimenez, M.B.A
Co-Founder and Managing Director, Aditum Ventures
David Goel
Founder & Managing General Partner, Matrix Capital Management
Jonathan MacQuitty, Ph.D.
Sector Head for Life Sciences, Lightspeed Ventures
Margarita Chavez, J.D.
Managing Director, AbbVie Ventures
Session IX: Artificial Intelligence Technologies
Moderator: James Zou, PhD | Co-Moderator: Mark Mercola, PhD
Full Session
Moderator: James Zou, Ph.D.
Assistant Professor of Biomedical Data Science and, by courtesy, of CS and of EE, Stanford University
Co-Moderator: Mark Mercola, Ph.D.
Professor of Medicine, Stanford University School of Medicine
Speakers:
Christopher Gibson, Ph.D.
Co-Founder, Chief Executive Officer, Recursion
Mapping and Navigating Biology at Scale
Daphne Koller, Ph.D.
Founder & Chief Executive Officer, Insitro
Transforming Drug Discovery using Digital Biology
Karen Akinsanya, Ph.D.
President, R&D Therapeutics, Schrödinger
Transitioning from Computer-aided and Empirical Drug Discovery to Computer-driven and Structure-based Drug Discovery
Panel Discussion
Mapping and Navigating Biology at Scale
Christopher Gibson, PhD
Co-Founder, Chief Executive Officer, Recursion
Transforming Drug Discovery using Digital Biology
Daphne Koller, PhD
Founder & CEO, Insitro
Transitioning from Computer-aided and Empirical Drug Discovery to Computer-driven and Structure-based Drug Discovery
Karen Akinsanya, PhD
Chief Biomedical Scientist, Schrödinger
Panel Discussion
Moderator: James Zou, Ph.D.
Assistant Professor of Biomedical Data Science and, by courtesy, of CS and of EE, Stanford University
Co-Moderator: Mark Mercola, Ph.D.
Professor of Medicine, Stanford University School of Medicine
Speakers:
Christopher Gibson, Ph.D.
Co-Founder, Chief Executive Officer, Recursion
Daphne Koller, Ph.D.
Founder & Chief Executive Officer, Insitro
Karen Akinsanya, Ph.D.
President, R&D Therapeutics, Schrödinger
Session X: Research Development IV
Moderator: Peter Kim, PhD | Co-Moderator: Kuldev Singh, MD
Full Session
Moderator: Peter Kim, Ph.D.
Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University
Co-Moderator: Kuldev Singh, M.D.
Professor of Ophthalmology, Stanford University School of Medicine
Speakers:
Andrew Plump, M.D., Ph.D.
President, Research & Development, Takeda Pharmaceutical
Creating a Patient-Driven, Science-First R&D Organization
Aviv Regev, Ph.D.
Executive Vice President, Research and Early Development, Genentech
James Bradner, M.D.
President, Novartis Institutes of BioMedical Research
Merdad Parsey, M.D., Ph.D.
Chief Medical Officer, Gilead
Development of Treatments for the Globe: from HIV to COVID-19
Panel Discussion
Creating a Patient-driven, Science-first R&D Organization
Andrew Plump, MD, PhD
President, R&D, Takeda Pharmaceutical
Development of Treatments for the Globe: from HIV to COVID-19
Merdad Parsey, MD, PhD
Chief Medical Officer, Gilead
Panel Discussion
Moderator: Peter Kim, Ph.D.
Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University
Co-Moderator: Kuldev Singh, M.D.
Professor of Ophthalmology, Stanford University School of Medicine
Speakers:
Andrew Plump, M.D., Ph.D.
President, Research & Development, Takeda Pharmaceutical
Aviv Regev, Ph.D.
Executive Vice President, Research and Early Development, Genentech
James Bradner, M.D.
President, Novartis Institutes of BioMedical Research
Merdad Parsey, M.D., Ph.D.
Chief Medical Officer, Gilead
Day 2 Closing Remarks
Joseph Wu, MD, PhD
Director, Stanford CVI
Simon H. Stertzer, MD, Professor, Department of Medicine and Radiology
Stanford University School of Medicine